Jacquelyn Russell1, Melisa L Wong2, Lynda Mackin1, Steven M Paul1, Bruce A Cooper1, Marilyn Hammer3, Yvette P Conley4, Fay Wright5, Jon D Levine2, Christine Miaskowski6. 1. School of Nursing, University of California, San Francisco, California, USA. 2. School of Medicine, University of California, San Francisco, California, USA. 3. Department of Nursing, Mount Sinai Medical Center, New York, New York, USA. 4. School of Nursing, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. 5. Rory Meyers College of Nursing, New York University, New York, New York, USA. 6. School of Nursing, University of California, San Francisco, California, USA. Electronic address: chris.miaskowski@ucsf.edu.
Abstract
CONTEXT: Patients with lung cancer who undergo chemotherapy (CTX) experience multiple symptoms. Evaluation of how these symptoms cluster together and how these symptom clusters change over time are salient questions in symptom clusters research. OBJECTIVES: The purposes of this analysis, in a sample of patients with lung cancer (n = 145) who were receiving CTX, were to 1) evaluate for differences in the number and types of symptom clusters at three time points (i.e., before their next cycle of CTX, the week after CTX, and two weeks after CTX) using ratings of symptom occurrence and severity and 2) evaluate for changes in these symptom clusters over time. METHODS: At each assessment, a modified version of the Memorial Symptom Assessment Scale was used to assess the occurrence and severity of 38 symptoms. Exploratory factor analyses were used to extract the symptom clusters. RESULTS: Across the two symptom dimensions (i.e., occurrence and severity) and the three assessments, six distinct symptom clusters were identified; however, only three of these clusters (i.e., lung cancer specific, psychological, nutritional) were relatively stable across both dimensions and across time. Two additional clusters varied by time but not by symptom dimension (i.e., epithelial/gastrointestinal and epithelial). A sickness behavior cluster was identified at each assessment with the exception of the week before CTX using only the severity dimension. CONCLUSION: Findings provide insights into the most common symptom clusters in patients with lung cancer undergoing CTX. Most common symptoms within each cluster appear to be relatively stable across the two dimensions, as well as across time.
CONTEXT: Patients with lung cancer who undergo chemotherapy (CTX) experience multiple symptoms. Evaluation of how these symptoms cluster together and how these symptom clusters change over time are salient questions in symptom clusters research. OBJECTIVES: The purposes of this analysis, in a sample of patients with lung cancer (n = 145) who were receiving CTX, were to 1) evaluate for differences in the number and types of symptom clusters at three time points (i.e., before their next cycle of CTX, the week after CTX, and two weeks after CTX) using ratings of symptom occurrence and severity and 2) evaluate for changes in these symptom clusters over time. METHODS: At each assessment, a modified version of the Memorial Symptom Assessment Scale was used to assess the occurrence and severity of 38 symptoms. Exploratory factor analyses were used to extract the symptom clusters. RESULTS: Across the two symptom dimensions (i.e., occurrence and severity) and the three assessments, six distinct symptom clusters were identified; however, only three of these clusters (i.e., lung cancer specific, psychological, nutritional) were relatively stable across both dimensions and across time. Two additional clusters varied by time but not by symptom dimension (i.e., epithelial/gastrointestinal and epithelial). A sickness behavior cluster was identified at each assessment with the exception of the week before CTX using only the severity dimension. CONCLUSION: Findings provide insights into the most common symptom clusters in patients with lung cancer undergoing CTX. Most common symptoms within each cluster appear to be relatively stable across the two dimensions, as well as across time.
Authors: Xin Shelley Wang; Diane L Fairclough; Zhongxing Liao; Ritsuko Komaki; Joe Y Chang; Gary M Mobley; Charles S Cleeland Journal: J Clin Oncol Date: 2006-09-20 Impact factor: 44.544
Authors: Claire J Han; Kerryn Reding; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Kord M Kober; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-08-09 Impact factor: 3.612
Authors: Carolyn S Harris; Kord M Kober; Bruce Cooper; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Steven Paul; Jon D Levine; Christine A Miaskowski Journal: Support Care Cancer Date: 2022-05-11 Impact factor: 3.603
Authors: Carolyn S Harris; Kord M Kober; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Christine A Miaskowski Journal: BMJ Support Palliat Care Date: 2021-12-17 Impact factor: 3.568
Authors: Rachel A Pozzar; Marilyn J Hammer; Bruce A Cooper; Kord M Kober; Lee-May Chen; Steven M Paul; Yvette P Conley; Frances Cartwright; Fay Wright; Jon D Levine; Christine Miaskowski Journal: Cancer Nurs Date: 2021-09-23 Impact factor: 2.760
Authors: Stephen Breazeale; Susan G Dorsey; Joan Kearney; Samantha Conley; Sangchoon Jeon; Brad Yoo; Nancy S Redeker Journal: Res Nurs Health Date: 2020-12-25 Impact factor: 2.228